GATM gene variants and statin myopathy risk
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other investigators, however, were unable to replicate the association between the rs9806699 GATM SNP and statin myopathy.117”
From Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) · cites this paper as [117]
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
Mangravite, L. M., Engelhardt, B. E., Medina, M. W., Smith, J. D., Brown, C. D., Chasman, D. I., Mecham, B. H., Howie, B., Shim, H., Naidoo, D., et al. (2013) · Nature · doi:10.1038/nature12508 · Cited by 224 · cited 3×
“We have extended our metaanalysis to include the study data reported in the accompanying Comments by Carr et al.(2) and Floyd et al.”
BackgroundMethodInfluentialCarr, D. F., O’Meara, H., Jorgensen, A. L., Campbell, J., Hobbs, M., McCann, G., van Staa, T., & Pirmohamed, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.161 · Cited by 147
Self-citationO’Meara, H., Carr, D. F., Evely, J., Hobbs, M. R., McCann, G., van Staa, T. P., & Pirmohamed, M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12269 · Cited by 14
Self-citation
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
“117 Clearly, further studies will be required to determine a mechanistic basis for a contribution of genetic variation in GATM to the risk of SAMS.”
Effects of statins on mitochondrial pathways
Mollazadeh, H., Tavana, E., Fanni, G., Bo, S., Banach, M., Pirro, M., von Haehling, S., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12654 · Cited by 249
“However, these data were not replicated in subsequent studies.(120,121) Areas of uncertainty still exist on this topic.”
Mancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 250
Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac020 · Cited by 190
Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 196
Self-citationStatin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
Vinci, P., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Mearelli, F., Biasinutto, C., Fiotti, N., Di Girolamo, F. G., & Biolo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111687 · Cited by 174
Pharmacogenomics of statins: understanding susceptibility to adverse effects
Kitzmiller, J., Mikulik, E., Dauki, A., Mukherjee, C., & Luzum, J. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s86013 · Cited by 90
Treatment Options for Statin-Associated Muscle Symptoms
Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 84
Pharmacogenetics of Statin-Induced Myotoxicity
Kee, P. S., Chin, P. K. L., Kennedy, M. A., & Maggo, S. D. S. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.575678 · Cited by 76
“This was supported by further research on 150 SIM cases and 587 statin-exposed control patients (Carr et al., 2014).”
ResultBrunham, L. R., Baker, S. K., Mammen, A. L., Mancini, G. B. J., & Rosenson, R. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy119 · Cited by 75
Carr, D. F., Francis, B., Jorgensen, A., Zhang, E., Chinoy, H., Heckbert, S. R., Bis, J. C., Brody, J. A., Floyd, J. S., Psaty, B. M., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1557 · Cited by 66
“The genetic association of statin myopathy with the GATM gene(16) has also not been replicated.(17,18) Utilizing patients with statin myopathy recruited via CPRD,(19) the aims of our study were twofold: to undertake a genomewide association study (GWAS) to identify novel genetic risk factors predisposing individuals t…”
BackgroundSelf-citationAdvances in statin adverse reactions and the potential mechanisms: A systematic review
Zeng, W., Deng, H., Luo, Y., Zhong, S., Huang, M., & Tomlinson, B. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.020 · Cited by 72
“Unfortunately, however, the correlation between the GATM gene and SAMS has not been confirmed by several other studies [84],. Case-control analyses found no correlation between GATM variants and SAMS risk.”
Floyd, J. S., Bloch, K. M., Brody, J. A., Maroteau, C., Siddiqui, M. K., Gregory, R., Carr, D. F., Molokhia, M., Liu, X., Bis, J. C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218115 · Cited by 54
Self-citationExpert opinion: the therapeutic challenges faced by statin intolerance
Patel, J., Martin, S. S., & Banach, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1197202 · Cited by 49
Elam, M. B., Majumdar, G., Mozhui, K., Gerling, I., VERA, S. R., Fish-Trotter, H. L., Williams, R. W., Childress, R. D., & Raghow, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181308 · Cited by 59
Luzum, J. A., Kitzmiller, J. P., Isackson, P. J., Ma, C., Medina, M. W., Dauki, A. M., Mikulik, E., Ochs‐Balcom, H. M., & Vladutiu, G. D. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.003 · Cited by 46
“Carr et al. (2014) reported an odds ratio = 0.94 (p = 0.68), and Floyd et al. (2014) reported an odds ratio = 0.84 (95% CI = 0.52–1.36; p = 0.49; excluding fibrate users) for the GATM rs9806699 A allele.”
InfluentialGenetic and immunologic susceptibility to statin-related myopathy
Patel, J., Superko, H. R., Martin, S. S., Blumenthal, R. S., & Christopher‐Stine, L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.025 · Cited by 42
Laufs, U., Scharnagl, H., & März, W. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000236 · Cited by 43
GATM locus does not replicate in rhabdomyolysis study
Floyd, J. S., Bis, J. C., Brody, J. A., Heckbert, S. R., Rice, K. M., & Psaty, B. M. (2014) · Nature · doi:10.1038/nature13629 · Cited by 29
“A fixed-effects meta-analysis yielded the following P values: rs9806699 (Marshfield, Carr et al. and Floyd et al.)”
InfluentialPersonalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy
Ahangari, N., Doosti, M., Ghayour‐Mobarhan, M., Sahebkar, A., Ferns, G. A., & Pasdar, A. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1800074 · Cited by 32
Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group
Stock, J. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.049 · Cited by 21
Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France
Coste, J., Billionnet, C., Rudnichi, A., Pouchot, J., Dray‐Spira, R., Giral, P., & Zureik, M. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318776831 · Cited by 22
Liu, M., Fan, F., Zhang, Y., & Li, J. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03019-3 · Cited by 17
Creatine as a Candidate to Prevent Statin Myopathy
Balestrino, M., & Adriano, E. (2019) · Biomolecules · doi:10.3390/biom9090496 · Cited by 14
“Although the association between the GATM polymorphism and statin myopathy was challenged [42,43], Mangravite et al.”
BackgroundMuscle phenotype of AGAT- and GAMT-deficient mice after simvastatin exposure
Sasani, A., Hornig, S., Grzybowski, R., Cordts, K., Hanff, E., Tsikas, D., Böger, R. H., Gerloff, C. P., Isbrandt, D., Neu, A. D., et al. (2019) · Amino Acids · doi:10.1007/s00726-019-02812-4 · Cited by 14
Xiang, Q., Zhang, X., Mu, G., Wang, Z., Liu, Z., Xie, Q., Hu, K., Zhang, Z., Ma, L., Jiang, J., et al. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03029-1 · Cited by 13
Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies
Sridharan, K., & Sivaramakrishnan, G. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328356429250315163111 · Cited by 5
Zhuyuan, Y., Meng, X., Zong, Z., Song, Q., Huo, Y., & Chen, H. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120570 · Cited by 5
Mangravite, L. M., Engelhardt, B. E., Stephens, M., & Krauss, R. M. (2014) · Nature · doi:10.1038/nature13630 · Cited by 4
Identifying Genetic Modulators of Statin Response Using Subject-Derived Lymphoblastoid Cell Lines
Kuang, Y., Theusch, E., Krauss, R. M., & Medina, M. W. (2021) · Pharmacogenomics · doi:10.2217/pgs-2020-0197 · Cited by 5
Statinassoziierte Muskelsymptome und Statinmyopathie
Schneider, I., & Zierz, S. (2019) · Neurologie up2date · doi:10.1055/a-0794-9660 · Cited by 3
Sychev, D. A., Оstroumova, Т. М., Ostroumova, O. D., Кочетков, А. И., Владимировна, Б. С., & Mironova, E. V. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-3-252-270 · Cited by 2
Investigation of the Association of GATM Gene Polymorphisms with Statin-Induced Myopathy
Hussain, A., Zakria, M., Tariq, S. A., Rauf, M. A., Ahmad, J., Rasool, M. F., & Ali, I. (2023) · Precision Medicine Communications · doi:10.55627/pmc.003.02.0430 · Cited by 3
Yang, R., Hu, N., Chen, H., 李文强, & Zheng, T. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06224-y · Cited by 1
Distrofias musculares, miopatías metabólicas y tóxicas
Cabrera‐Serrano, M. (2015) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2015.03.004
Metadata
- Authors
- Carr, D. F., Alfirevic, A., Johnson, R., Chinoy, H., van Staa, T., & Pirmohamed, M.
- Affiliations
- University of Liverpool (GB)
- University of Manchester (GB)
- Corresponding author
- Alfirevic, A.
- Venue
- Nature
- Published
- 2014-09-17
- Volume
- 513
- Issue
- 7518
- Pages
- E1-E1
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2090393435
- Cited by
- 35
- References
- 4
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 6 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 2
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10064, CL-2006-06-010)
- Versus Arthritis (18474)
- Medical Research Council (MC_qA137929, MR/K006665/1, MC_PC_13042, MR/L006758/1)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- GATM, statin-induced myopathy, expression quantitative trait loci, simvastatin, genetic susceptibility, replication of genetic associations, lymphoblastoid cell lines, statin exposure
- MeSH terms
- Amidinotransferases, Gene Expression Regulation, Humans, Muscular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Quantitative Trait Loci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.